Notizie e Video - ALMIRALL

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This year's event features a comprehensive program aimed at sharing state-of-the-art scientific knowledge on skin diseases, their treatment, and clinical best practice. The Skin Academy is a unique opportunity for collaboration, bringing together a broad range of leading experts and clinicians from...

Almirall, S.A. (ALM) , a global pharmaceutical company dedicated to medical dermatology presents five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting - including new data on tirbanibulin, a topical treatment for actinic keratosis (AK) and progress of its early-stage asset LAD191 , a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). These presentations provide valuable insights into patient outcomes, safety, and...

Almirall, S.A. (ALM): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223477772/en/ Almirall HQ in Barcelona (Photo: Business Wire) Financial highlights (€ rounded million) 2024 2023 Variation Total Revenue 990.6 898.8 10.2% Net Sales 985.7 894.5 10.2% Other Income 4.9 4.3 14.0% Gross Profit 637.4 581.4 9.6% % of sales 64.7% 65.0% 10.6% Total EBITDA 192.6 174.1 Normalized Net Income 25.6 15.6 64.2% Net Income 10.1 (38.5) n.m "2024...

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its...

Almirall, S.A. (ALM) , a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales increased by 7.9% YoY to a total of €727.6 MM, EBITDA was €142.2 MM (increase of 2.9% YoY) driven by higher sales growth, with a gross margin of...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results. Financial highlights (€ rounded million) H1 2023 H1 2022 Variation Net Sales 466.1 436.6 6.8% Total EBITDA 101.3 107.6 -5.9% Net Income 12.0 27.3 -56.0% Normalized Net Income 11.6 27.6 -58.0% Summary of results Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri ® (tildrakizumab) significantly improved wellbeing in patients with moderate-to-severe plaque psoriasis achieving a wellbeing status similar to the general population 1 after 16 weeks, which was maintained up to week 28 ¡Error! Marcador no definido. . These first results of the POSITIVE study were presented in a poster at the 25 th World Congress of Dermatology, held in...

Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of people living with psoriatic disease believe that it negatively affects their daily activities, causing a heavy physical, emotional and social burden that affects their mental health 1 and wellbeing 2 . Despite its high prevalence - approximately 1.52% of the UK population (1.01 million people estimated)...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital increase announced yesterday evening (the “ Capital Increase ”) following completion of the accelerated book-building offering, which was carried out by J.P. Morgan and BNP PARIBAS as Joint Global Coordinators and Joint Bookrunners. As a result of the Capital Increase, the Company has raised a...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “ Capital Increase ”) for a total aggregate amount (including nominal value and share issue premium) of approximately EUR 200,000,000 by issuing new ordinary shares of the Company belonging to the same class and series as the outstanding shares (the “ New Shares ”) in consideration for cash contributions. The...

...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results. Financial highlights (€ rounded million) Q1 2023 Q1 2022 Variation Net Sales 232.0 218.8 6.0% Total EBITDA 51.8 59.6 (13.1%) Net Income 7.7 20.4 (62.3%) Normalized Net Income 7.7 20.5 (62.4%) Summary of results Net Sales reached €232.0 MM, a +6% year-on-year increase underpinned by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab’s stable and long-lasting results at one year of treatment in...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies (NCT04146363 and NCT04178967), evaluating lebrikizumab as monotherapy in adult and...

Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today. Financial highlights (€ rounded million) 2022 2021 Variation Total Revenues 878.5 836.5 5.0% Net Sales 863.2 827.2 4.4% Other Income 15.3 9.3 64.5% Gross Profit 572.9 571.3 0.3% % of sales 66.4% 69.1% EBITDA 198.3 235.6 (15.8%) Normalized Net Income 33.5 81.4 (55.8%) * Core results excludes AstraZeneca/Covis contribution: Deferred Income and Other Income. From...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023. Carlos Gallardo, Chairman and CEO of Almirall , is scheduled to give a presentation at 9 am Pacific Standard Time (6pm CET) on January 10 th , 2023. The presentation will be available at https://www.almirall.com/investors Almirall’s executive team will host...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE , ( F r A mework for C l I nica L tr I al participants’ da TA reutilization for a fully T ransparent and E thical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem . FACILITATE main objective is to...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results. Financial highlights (€ rounded million) 9M 2022 9M 2021 Variation Core Net Sales* 633.8 601.7 5.3% Core EBITDA* 134.0 164.2 (18.4%) Total EBITDA 146.4 181.2 (19.2%) Net Income 10.9 (39.4) n.m Normalized Net Income 32.7 61.5 (46.8%) * Core results excludes AstraZeneca and Covis contribution: Deferred Income and Other Income. From 2022 onwards, there is no difference...

Almirall opens a new subsidiary for the Czech Republic and Slovakia PR Newswire BARCELONA, Spain, Nov. 8, 2022 The company is appointing David Festa as General Manager of the Czech Republic and Slovakia affiliate The new affiliate responds to Almirall's expansion strategy to support the company's gradual growth and to offer its treatments to a wider number of people living with dermatological diseases Almirall will start commercializing Ilumetri ® ▼ (tildrakizumab) in these two countries for...

...